Published in:
Open Access
01-12-2009 | Research
A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs
Authors:
Eva Maria Hodel, Serej D Ley, Weihong Qi, Frédéric Ariey, Blaise Genton, Hans-Peter Beck
Published in:
Malaria Journal
|
Issue 1/2009
Login to get access
Abstract
Background
In order to provide a cost-effective tool to analyse pharmacogenetic markers in malaria treatment, DNA microarray technology was compared with sequencing of polymerase chain reaction (PCR) fragments to detect single nucleotide polymorphisms (SNPs) in a larger number of samples.
Methods
The microarray was developed to affordably generate SNP data of genes encoding the human cytochrome P450 enzyme family (CYP) and N-acetyltransferase-2 (NAT2) involved in anti-malarial drug metabolisms and with known polymorphisms, i.e. CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NAT2.
Results
For some SNPs, i.e. CYP2A6*2, CYP2B6*5, CYP2C8* 3, CYP2C9*3/*5, CYP2C19*3, CYP2D6*4 and NAT2*6/*7/*14, agreement between both techniques ranged from substantial to almost perfect (kappa index between 0.61 and 1.00), whilst for other SNPs a large variability from slight to substantial agreement (kappa index between 0.39 and 1.00) was found, e.g. CYP2D6*17 (2850C>T), CYP3A4*1B and CYP3A5*3.
Conclusion
The major limit of the microarray technology for this purpose was lack of robustness and with a large number of missing data or with incorrect specificity.